Recently [Anthony Francis-Jones] decided to take a closer look at the inhaler that his son got prescribed for some mild breathing issues, specifically to teardown the mechanical counter on it.

People using the popular corticosteroid inhalers Flovent HFA or Flovent Diskus to treat their asthma will need to switch to a new product in 2024. Flovent manufacturer GlaxoSmithKline announced in ...

The go-to asthma inhaler prescribed by pediatricians for decades has been discontinued, and patients and families are paying a steep price. Discontinued Inhaler Devastates Families On Jan. 10, Laura ...

Concerns over health care’s carbon footprint typically revolve around issues like overly-air-conditioned hospitals and single-use medical supply waste. But researchers like Stanford University’s ...

GINA 2026 no longer endorses a SABA alone for asthma, yet albuterol labels still list only bronchospasm. Airsupra adds exacerbation risk reduction for adults.

U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its widely used asthma inhaler, Flovent HFA, from the market. One year after ...

A popular asthma inhaler was discontinued on Jan. 1, and the business move has left families scrambling to find a replacement for their kids. Flovent was one of the most commonly prescribed drugs for ...

Facing criticism over its pricing, Boehringer Ingelheim plans to cap out-of-pocket costs at $35 a month for its entire line of inhalers that are used to combat asthma and chronic obstructive pulmonary ...

More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says. In 2024, GlaxoSmithKline withdrew Flovent from the market.

EDITOR’S NOTE: Dr. Edith Bracho-Sanchez is a primary care pediatrician, director of pediatric telemedicine and assistant professor of pediatrics at Columbia University Irving Medical Center. Flovent, ...

GSK used a ploy known as “device hopping,” in which a branded inhaler is retired and succeeded by a follow-on inhaler with the same active ingredients but new patent and regulatory protection periods.

A cross-sectional study of 61 COPD patients in Turkey found moderate oral health scores and that most received no oral health ...